Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 26:17:17562864241258787.
doi: 10.1177/17562864241258787. eCollection 2024.

A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report

Xuefen Chen  1   2 , Ziyan Shi  3 , Rui Wang  3 , Hongyu Zhou  4
Affiliations
Case Reports

A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report

Xuefen Chen et al. Ther Adv Neurol Disord. .

Abstract

Inebilizumab is one of the monoclonal antibodies approved as maintenance therapy for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (NMOSD). It is a humanized monoclonal antibody targeting cluster of differentiation 19 (CD19). Common adverse reactions include urinary tract infections, nasopharyngitis, arthralgia, infusion reactions, headaches and a decrease in immunoglobulin levels. Here, we present a case of an NMOSD patient who experienced transient hyperCKaemia after the use of inebilizumab. The adverse reactions of this very rare monoclonal antibody drug improved after discontinuation.

Keywords: adverse effect; case report; hyperCKaemia; inebilizumab; neuromyelitis optica spectrum disorder.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Spinal cord MRI taken at the first attack. Sagittal (a) and axial (b) MR images of the thoracic spine show a long-segment T2 hyperintensity. MRI, magnetic resonance imaging.
Figure 2.
Figure 2.
Spinal cord MRI taken during the inflammatory myelitis episode. Sagittal (a–c) and axial (d–f) MR images of the thoracic spine show a long-segment T2 hyperintensity, with increased enhancement observed. MRI, magnetic resonance imaging.
Figure 3.
Figure 3.
Timeline of the patient’s condition with relevant data of past episodes. (a) Relapse and treatment. (b) CK values. The red arrow indicates the time points of inebilizumab usage. AM, acute myelitis; CK, creatinine kinase; MMF, mycophenolate mofetil; ON, optic neuritis; RTX, rituximab.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cree BAC, Bennett JL, Kim HJ, et al.. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394: 1352–1363. - PubMed
    1. Marignier R, Bennett JL, Kim HJ, et al.. Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2021; 8: e978. - PMC - PubMed
    1. Frampton JE. Inebilizumab: first approval. Drugs 2020; 80: 1259–1264. - PMC - PubMed
    1. Liu SW, Velez NF, Lam C, et al.. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol 2013; 149: 1204–1208. - PubMed
    1. He D, Li Y, Dai Q, et al.. Myopathy associated with neuromyelitis optica spectrum disorders. Int J Neurosci 2016; 126: 863–866. - PubMed

Publication types

LinkOut - more resources